Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec SE Regains the Rights to All P2X3 Assets | Contract Pharma

What are you searching for?

Sign in
Breaking News

Evotec SE Regains the Rights to All P2X3 Assets

Bayer discontinues clinical development candidate eliapixant.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Evotec SE has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance.
 
Following a review of the available data, Bayer concluded that the overall benefit no longer outweighs the risk in the actively pursued indications.
 
As a consequence of Bayer’s decision, Evotec regains the rights to all P2X3 assets. The company will evaluate the underlying data as soon as they are made available and will evaluate all options.
 
This decision has no impact on the overall strategic goals as outlined in Action Plan 2025.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics